Bookrunners Citi, Leerink Swann assist; Canaccord is lead co-manager
By Devika Patel
Knoxville, Tenn., June 3 - Anthera Pharmaceuticals, Inc. priced a $50 million public sale of stock with a $7.5 million greenshoe in a prospectus supplement filed Friday with the Securities and Exchange Commission. The deal was announced Thursday.
The company will sell 6,666,667 common shares at $7.50 apiece. The price per share is a 3.97% discount to the June 2 closing share price of $7.81.
Citi and Leerink Swann are the joint bookrunning managers, and Canaccord Genuity is the lead co-manager.
Settlement is expected June 8.
Proceeds will be used for general corporate purposes.
Anthera, based in Hayward, Calif., is a biopharmaceutical company.
| Issuer: | Anthera Pharmaceuticals, Inc.
|
| Issue: | Common shares
|
| Amount: | $50 million
|
| Greenshoe: | $7.5 million
|
| Shares: | 6,666,667
|
| Price: | $7.50
|
| Warrants: | No
|
| Agents: | Citi and Leerink Swann, Canaccord Genuity
|
| Announcement date: | June 2
|
| Pricing date: | June 3
|
| Settlement date: | June 8
|
| Stock symbol: | Nasdaq: ANTH
|
| Stock price: | $8.10 at close June 3
|
| Market capitalization: | $267.09 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
